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T cell immunomodulation by 
clinically used allogeneic human 
cancellous bone fragments: a 
potential novel immunotherapy 
tool
Yasser M. El-Sherbiny1,2,3, Jehan J. El-Jawhari1,2,3, Timothy A. Moseley4, Dennis McGonagle1,3 
& Elena Jones1,3
Multipotential stromal cells (MSCs) demonstrate strong immunomodulation capabilities following 
culture expansion. We have previously demonstrated that human cancellous bone fragments 
(CBFs) clinically used as viable allografts for spinal fusion have resident MSCs that exhibit T cell 
immunomodulation after monolayer expansion. This study investigated the immunomodulatory 
ability of these CBFs without MSC culture-expansion. CD4 positive T cells were induced to proliferate 
using CD3/CD28 stimulation and added to CBFs at different ratios of T cells per gram of CBF. A dose-
dependent suppressive effect on T cell proliferation was evident and correlated with increased culture 
supernatant levels of TGF-ß1, but not PGE2. CBF-driven immunosuppression was reduced in co-cultures 
with TGF-ß neutralising antibodies and was higher in cell contact compared to non-contact cultures. 
CBF gene expression profile identified vascular cell adhesion molecule-1, bone marrow stromal antigen 
2/CD317 and other interferon signalling pathway members as potential immunomodulatory mediators. 
The CD317 molecule was detected on the surface of CBF-resident cells confirming the gene expression 
data. Taken together, these data demonstrate that human clinically used CBFs are inherently 
immunomodulatory and suggest that these viable allografts may be used to deliver therapeutic 
immunomodulation for immune-related diseases.
In the last decade, cellular therapy such as multipotential stromal cells (MSCs) has been used extensively for 
immunomodulation in the variety of clinical settings including graft-versus-host disease (GVHD), Crohn’s dis-
ease, rheumatoid arthritis, kidney transplantation, type II diabetes and multiple sclerosis with promising out-
comes1–3. MSCs are imbued with remarkable in vitro and in vivo immunomodulatory properties although initially 
defined based on their clonogenicity, high proliferative capacity and potential for trilineage differentiation to the 
bone, cartilage and fat lineages4,5. MSC immunomodulatory abilities include a substantial inhibition of stimulated 
CD4 or CD8 T-cell proliferation, suppression of proliferation and antibody formation by B cells, and modulation 
of the expansion as well as promoting the differentiation of monocytes into M2 macrophages with immunosup-
pressive phenotype6,7. Although available, MSC-based therapies require extensive controlled good manufacturing 
practice (GMP)-grade culturing and remain highly variable in terms of MSC tissue source, ex vivo manipulation, 
cell doses and methods of delivery. Additionally, intravenously injected cultured MSCs are known to be trapped 
in lungs8 whereas locally-delivered cells are rapidly degraded after administration9,10 and thus have a short time 
window for their immunomodulatory action.
We have previously shown that human cancellous bone fragments (CBFs) clinically-used as cellular bone 
allografts to augment bone regeneration primarily for spine fusion, contain bone-resident MSCs capable (after 
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monolayer expansion) of the suppression of stimulated CD4+ T-cell proliferation, in addition to their classical 
MSC tri-lineage differentiation abilities11. These CBFs are produced from cadaveric human cancellous bone using 
extensive immuno-depletion bone washing procedures and are histologically characterised by an almost complete 
removal of blood-lineage cells from the bone marrow cavity. We have previously shown that these CBFs were also 
enriched for MSC-lineage cells including bone-lining cells and bone-embedded osteocytes. Phenotypically, enzy-
matically extracted cells from these CBFs contained high proportions of CD45−CD271+ cells11, a recognised phe-
notype of native bone-resident MSCs12–14. Based on this, we hypothesised that these CBFs could have an innate 
immunomodulatory activity partially related to MSC content. In support of this hypothesis, immunosuppressive 
effects of allogeneic bone grafts have been previously reported in several independent animal studies15–17. The aim 
of this study was, therefore, to examine the immunomodulatory capacity of these CBFs without any manipulation 
or MSC expansion, in co-cultures with allogeneic CD3/CD28-stimulated CD4 T cells.
We found dose-dependent suppression of CD4 T-cell proliferation and an increase in TGF-ß1 levels in these 
co-cultures, indicating an intrinsic immunomodulatory potential of CBFs. Gene expression analysis of CBFs 
prior to co-cultures provided a list of candidate immunomodulatory molecules potentially eliciting immunomod-
ulation, with CD317 being confirmed at the protein level. Altogether, these findings suggest that these CBFs may 
potentially be used to elicit therapeutic immunomodulation in the clinical settings.
Results and Discussion
The effect of cancellous bone fragments (CBFs) on CD3/CD28-stimulated T-cell proliferation. 
The co-culture of MSCs with alloantigen- or CD3/CD28-stimulated T cells particularly purified CD4 T cells is a 
standard assay to study immunomodulatory effects of MSCs on the adaptive immune cells11,18–20. In these assays, 
T cell:MSC ratios are set at 1:1 to 10:1 T cells per MSC. The same assay was applied in our CBF experiments, but 
the co-cultures were set up based on the addition of different numbers of activated CD4 T cells to tissue culture 
wells containing pre-weighted CBFs of the same weight. The reason for this method is that potential immuno-
modulation by CBFs could not be solely attributed to MSCs present in CBFs and the other cells such as osteopro-
genitors, osteocytes and the residual immune-lineage cells were present. On day 6 of co-culture, CD4 T cells were 
collected from culture supernatants and their proliferation suppression was analysed by flow cytometry following 
gating on the CD45+CD90−CD4+ population (Fig. 1a, top panel). Proliferation suppression was measured as 
T cell suppression index (SI), based on the degree of cell tracer dye dilution. Control culture wells included 
unstimulated T cells and stimulated T cells, both without CBFs. As expected, control stimulated T cells displayed 
multiple divisions (no suppression); this was assigned a T cell suppression index of zero (Fig. 1a, lower panel). 
As expected, no dye dilution was evident in unstimulated T cells control (Fig. 1a, lower panel). The highest sup-
pression (median SI of 71%) was observed at the lowest T cell:CBF ratio (5 × 105 T cells/gm CBF) (Fig. 1a, lower 
panel). With the increase of T cell: CBF ratios, a corresponding decrease in the average T-cell suppression index 
was detected (Fig. 1a, lower panel), which reached medians of 71, 64, 42 and 37% for 0.5, 1, 2, and 4 × 106 T cells/
gram of CBFs respectively (Fig. 1a, lower panel). Statistical analysis showed significant differences in suppression 
indices between different T cell: CBF ratios (Fig. 1b, left panel). This indicated the ability of CBFs to suppress the 
proliferation of CD4 T cells in a dose-dependent manner.
To illustrate the magnitude of CBF modulation on CD4 T cell proliferation in relation to standard 2D cultured 
MSCs, bone marrow-derived MSCs (bmMSCs) were used instead of CBFs and co-cultured with purified stimu-
lated CD4 T cells at 1:1, 2:1, 4:1, and 8:1 ratios11. The average 2D bmMSC-mediated T cell suppression indices had 
medians of 49, 39, 29 and 21% for T cell:MSC cell ratios of 1:1, 2:1, 4:1 and 8:1, respectively, and significantly dif-
ferent between the ratios (Fig. 1b, middle panel). These results demonstrated that in our experimental conditions, 
1 gm of CBFs provided CD4 T cell immunosuppressive effects corresponding to approximately 1.5 to 2 × 106 of 
2D cultured bmMSCs.
Soluble factors involved in CBF immunomodulation. To test if the suppression of CD4 T-cell prolifer-
ation can be induced via CBF secreted factors without their contact with T cells, the co-cultures were performed 
without direct contact between the T cells and CBFs. For this, CBFs and T cells were separated by transwell 
cell culture inserts. The results showed that although the T cell suppression indices were higher in T cell: CBF 
co-cultures compared to stimulated T cell positive control (zero SI), T cell suppression indices were on average 
2.8-fold lower compared to contact co-cultures (Fig. 1b, right panel). This indicated that soluble factors contrib-
uted to the observed immunomodulation, but they were not exclusive and cell contact-mediated mechanisms of 
immunosuppression were also involved.
PGE2 and TGF-ß1 are two well recognised soluble mediators of immunomodulation by MSCs on T cells1,6,21. 
To explore their involvement in CBF mediated T cell immunomodulation, co-cultures were set similarly so that 
the increasing numbers of T cells were added to the same weights of CBFs. Control wells included: media only, 
CBF in media only, and stimulated T cells only. Although PGE2 levels in these co-cultures were above those of 
media only and T cells only controls (Fig. 2a), they were in the lower range of PGE2 concentrations previously 
described for 2D cultured MSCs22,23 and showed no significant correlation with T cell proliferation suppression 
indices from the same cultures.
In contrast, significantly higher levels of TGF-ß1 in the supernatants from co-cultures of CBF with T cells at 
different ratios compared to all controls including CBF only controls were observed (Fig. 2b). TGF-ß1 levels were 
comparable to previously published for 2D MSC cultures22,24,25 and positively correlated with CBF T cell immu-
nomodulation (r = 0.673, p = 0.019) (Fig. 2c).
To confirm the mediating role of TGF-ß1, the effect of CBFs on CD3/CD28 stimulated T-cell proliferation was 
examined in the presence of TGF-ß neutralising antibody or isotype control and we used ratio 1 × 106 T cell/gm 
CBF for this experiment. The cell tracer peaks indicated more proliferation of T cells in the presence of TGF-ß 
neutralising antibodies compared to CBFs with isotype control antibody (Fig. 2d, left panel) and the suppression 
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indices in co-cultures of CBFs and stimulated T-cells in the presence of TGF-ß neutralising antibodies were mark-
edly lower compared to isotype control antibody (p = <0.05, Fig. 2d, right panel).
Immunomodulatory gene expression profile of the CBFs. As our co-culture data showed a possi-
bility for both cell contact-mediated and soluble factor-mediated immunosuppression by CBFs, we next per-
formed gene expression analysis in CBFs, in order to identify potential molecular candidates. Compared to 
fibroblasts, a common comparator for MSCs26, the top 50 highly-expressed genes in CBFs included mesenchymal 
lineage transcripts previously shown to be expressed in uncultured CD45−CD271+ bmMSCs and reflective of 
Figure 1. FACS gating strategy and experimental design of experiments to investigate the immunosuppressive 
expects of CBFs or bmMSCs on stimulated CD4+ T cells. (a) T cells present in the co-culture media were 
stained with antibodies against CD90, CD45 and CD4, and a viability dye 7AAD. Following the 7AAD/Side 
scatter gating for dead cell exclusion, CD45+CD90−CD4+ T cells were identified and analysed for proliferation 
suppression. Histograms representing the proliferation suppression analysis of CD45+CD90−CD4+ T cells 
cocultured for 5 days with 1 gm of CBFs (representative sample) at increasing T cell ratios. Colours represent 
cell generations detection, and calculated suppression index (SI) measured as % of suppression compared to 
no suppression control is indicated in the top left corner. (b) Comparison of T cell proliferation SIs in different 
co-culture conditions: 3D with CBFs (left panel), 2D with cultured bmMSCs (middle panel) and in transwell 
cultures with CBFs (right panel). Stim T cell – Stimulated T cell only (no suppression) control (Wilcoxon signed 
rank test, *p =  < 0.05, **p =  < 0.01).
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their multipotential nature (approximately 20% transcripts, Table 1). Interestingly, a similar number of genes (10 
genes or 20%) were categorised as immune response-associated molecules, two of which (Vascular cell adhesion 
molecule-1 (VCAM1) and S100 calcium binding protein A8 (S100A8)) were previously shown to be expressed in 
CD45−CD271+ MSCs27–29. VCAM1 is considered an essential adhesion molecule mediating MSC:T cell contacts 
during immunosuppression30. The roles of defensins and alarmins (S100 proteins), innate immune defence mole-
cules also highly expressed in CBFs (Table 1), remain poorly understood. However, recent evidence suggests that 
they may be mediating the homing and maintenance of hematopoietic progenitors in the vicinity of bone mar-
row stroma27,31. Several variants of osteopontin were highly expressed in CBFs; apart from being a well-known 
bone structural protein, osteopontin is also known as a regulator of the cross-talk between innate and adaptive 
immunity affecting T cell polarisation32. Interestingly, up-regulation of the osteopontin expression was previously 
noted in 3D cultured MSCs compared to their 2D counterparts33. Finally, CBFs also expressed higher levels of 
prostaglandin-endoperoxide synthase 2 (also known as Cox-2), an enzyme involved in the production of PGE2 
that, in addition to immunosuppression, has a role in the osteoblast maturation34.
To validate the gene array data, we tested the expression levels of selected genes using real-time PCR (Fig. 3a). 
The expression levels of all molecules selected for validation including native MSC specific molecules: SPP1, 
BGLAP, FABP4, and immune-related molecules: S100A8, VCAM1, ISG20 and SA10012, were considerably higher 
in CBFs compared to fibroblasts. The higher expression of NGFR, a gene encoding CD271 protein was used as a 
positive control and indicated the presence of native MSCs in CBFs (Fig. 3a). Additionally, S100A9 was tested as 
a marker of myeloid-derived suppressor cells35, another candidate immunomodulatory cell potentially present in 
CBFs, and showed high upregulation in CBFs compared to fibroblasts (Fig. 3a).
To get additional insights into CBF-specific immune-related molecules, all immune-related transcripts with 
at least 2-fold higher expression in CBFs compared to fibroblasts were further scrutinized for functional gene 
annotation clustering using the Database for Annotation, Visualization and Integrated Discovery (DAVID)36. The 
transcripts falling into an immunity cluster were next divided into ‘secreted’ and ‘other’ groups (Table 2). Notably, 
several molecules belonging to the interferon signalling pathway previously described as potentially mediat-
ing immunomodulation37 and bone turnover38 were found in the ‘others’ group (Table 2). Interestingly, MX1 
Figure 2. PGE2 (a) and TGF-ß1 (b) levels in the supernatants of co-cultures of CBFs and T cells. A stepwise 
increase in TGF-ß1 concentrations with increased numbers of T cells compared to CBF only (Mann-Whitney 
*p =  < 0.05) and other controls, in contrast to PGE2 where these trends were less obvious. (n ≥ 7) in all co-
culture ratios and (n = 3) in 8 × 106 T cells/gm of CBF. (c) Positive correlation between TGF-ß1 and T-cell SI in 
co-cultures of T cells and CBFs (spearman rho r = 0.673, p = <0.05). (d) CBF-driven immunomodulation in 
the presence of TGF-ß neutralising antibodies or isotype control antibody (co-culture ratio: 1 × 106 T cell/gm 
CBF) fluorescence histograms for a representative sample (left) and combined data (n = 3, right, paired t test, 
*p = <0.05).
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gene belonging to the interferon signalling pathway family has been previously described as a specific marker of 
osteolineage restricted MSCs in mice39, and found to be nearly 10-fold higher in CBFs compared to fibroblasts 
(Fig. 3a). The expression of bone marrow stromal antigen 2 (BST2)/CD317, in particular, was higher in CBFs 
compared to fibroblasts by both microarray and qPCR (Table 2 and Fig. 3a). This molecule has been previously 
shown to be expressed on bone marrow stromal cells40 and more recently, on their particular immunomodulatory 
subset37. To investigate the presence of CD317 on the surface of CBF-resident cells, we performed flow cytometry 
on cells enzymatically released from CBFs using collagenase. Following sequential gating on single alive cells, we 
confirmed positive BST2/CD317 protein expression on cell surface of three CBF samples tested (Fig. 3b).
We were mindful that CBFs contained residual cells of other lineages on the bone surface, which could be 
eliciting immunomodulation. Consistent with our previous findings11, CBFs used in immunomodulation exper-
iments contained cells with the phenotype of native bmMSCs (CD45−CD271+), which represented approxi-
mately 16% of all live cells enzymatically extracted from these CBFs [median (90% CI) 15.8% (5.3, 53.5), n = 9] 
(Fig. 3c, left panel). These cells also expressed classical MSC markers CD73, CD90 and CD105 (medians of 98, 
99 and 73% of CD45−CD271+ cells, respectively) confirming their MSC identity. Using the distinct phenotypes 
to identify different cell lineages, the relative proportions of endothelial-lineage cells (CD45−CD271−CD31+), 
erythroid-lineage cells (CD45−CD271−CD235a+), myeloid-lineage cells (CD45+CD271−CD33+), and 
lymphoid-lineage cells (CD45+CD271−CD3/19+) were next analysed (Fig. 3c, right panel). Lymphoid-lineage 
cells were found to be more abundant than other lineages while myeloid-lineage cells were least prevalent (Fig. 3c, 
right panel). Because of very low numbers of these myeloid-lineage cells and to maximise the use of sample, it 
was not feasible to include other markers or testing for exploring the presence of myeloid-derived suppressor cells 
(MDSCs) as reported35 in these CBFs. We also found a population of cells lacking the chosen markers (labelled as 
others) which could represent more mature MSC-lineage cells such as osteoblasts and adipocytes (Fig. 3c, right 
panel).
CD45−CD271+ MSCs express genes characteristic of both stromal fibroblasts and pericytes14,41. In addition 
to other unidentified CD45− cells, CBFs contain osteocytes inside the bone itself11. Osteogenically-differentiated 
MSCs in vitro have been reported to be immunomodulatory42,43. however, this has yet to be investigated for 
non-cultured osteocytes. Isolation and gene expression study of pure osteocytes, osteo- and adipogenically com-
mitted cells, MSCs and residual cells including MDSCs in CBFs would, therefore, be needed to address the rela-
tive contributions of different cell types to CBF gene expression pattern, and CBF immunomodulation in general.
In conclusion, this study is the first demonstration that natural 3D structures containing native uncultured 
MSCs possess high potential for immunomodulation. As such, these clinically available cellular allografts can 
be considered as a potential novel immunotherapy tool. As stated, several animal model studies have previously 
reported the ability of allogenic bone to prevent the rejection of transplanted organs15,17. In this context, our study 
demonstrated that clinically used CBFs could provide an ‘immuno-privileged niche’ capable of controlling adap-
tive immune cell responses in the allogeneic settings. These CBFs could, therefore, be further explored as local 
modulators of various inflammatory and immune-mediated diseases particularly those dependent on the CD4 T 
Gene name Gene code Fold-Difference Reference
Native MSC-specific molecules
Secreted phosphoprotein 1 (osteopontin), transcript variant 2 SPP1 119.7 28,41
Secreted phosphoprotein 1 (osteopontin), transcript variant 1 SPP1 64.1 28,41
Insulin-like growth factor binding protein 3, transcript variant 1 IGFBP3 38.1 28,29,41
Bone gamma-carboxyglutamate (gla) protein (osteocalcin) BGLAP 36.7 28,41
Lipoprotein lipase (LPL) LPL 33.9 28,29,41
Mesenteric estrogen-dependent adipogenesis MEDAG 30.6
SPARC-like 1 SPARCL1 26.1 28
Fatty acid binding protein 4, adipocyte FABP4 25.8 28,41
Insulin-like growth factor binding protein 3, transcript variant 1 IGFBP3 25.4 28,29,41
Immune related molecules
S100 calcium binding protein A8 (S100A8) S100A8 62.8 28
Interleukin 6 (interferon, beta 2) IL6 61.8
Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase) PTGS2 40.7
Defensin, alpha 1 DEFA1 40.3
Vascular cell adhesion molecule 1 VCAM1 25.8 27–30
Cathelicidin antimicrobial peptide CAMP 24.3
Interferon stimulated exonuclease gene 20 kDa ISG20 24.2
Defensin, alpha 1 LOC653600 23
Defensin, alpha 3, neutrophil-specific DEFA3 22.5
S100 calcium binding protein A12 S100A12 22.4
Table 1. MSC-specific and immune related molecules from the list of 50 top highly expressed genes in CBFs 
compared to fibroblasts. Immune related molecules were classified based on gene ontology and KEGG pathway 
analysis using STRING. Native MSC-specific molecules were selected based on published literature.
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cell response. Further studies are needed to address the relative contributions of the different cell populations in 
CBFs including MSCs, osteocytes and other stromal- and immune-lineage cells, and also the potential effects of 
matrix-embedded proteins.
There is already good evidence for the safety of CBF implants in clinical practice since over 250,000 of these 
allografts have been used successfully in bone fusion procedures without any reports of tissue rejection in the 
clinical literature summarised in11. We propose that these allografts could be repurposed to provide site-specific 
immunomodulation, for example by being locally implanted within a permeable barrier (mesh), which can allow 
free movement of cells and signals. Our previous study has shown the expansion of MSCs in CBFs in long-term in 
vitro culture11 suggesting that CBF-driven immunomodulation may be maintained longer than a standard short 
‘window of opportunity’ common for transplanted 2D cultured MSCs. Future study is needed to investigate the 
Figure 3. The analysis of candidate immunomodulatory molecules and cell populations in CBFs prior to 
immunomodulation experiments. (a) Immune-related and native MSC-specific gene expression by qPCR 
(bars represent mean values for n = 3 samples of CBFs and fibroblasts. (b) Gating strategy for flow cytometry 
detection of cell surface CD317 expression on enzymatically-extracted CBF-resident cells. Overlaid histograms 
for isotype control (grey line) and CD317 antibody (black line) on live single cells. (c) Cell populations released 
from CBFs and identifying CD45−CD271+ native MSCs and other lineage cells present in CBFs. FACS plot 
showing a representative sample (left) and combined data (n = 4, right).
www.nature.com/scientificreports/
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Gene name Gene code Fold-Change
Immune response: secreted
S100 calcium binding protein A8 S100A8 62.8
Interleukin 6 IL6 61.8
Defensin alpha 1 DEFA1 40.3
Complement factor D CFD 31.6
Cathelicidin antimicrobial peptide CAMP 24.3
Defensin alpha 3 DEFA3 22.5
S100 calcium binding protein A12 S100A12 22.4
Lipocalin 2 LCN2 14
Peptidoglycan recognition protein 1 PGLYRP1 12
Complement factor B CFB 6.8
Ficolin 1 FCN1 6.8
CD14 molecule CD14 5.1
Defensin alpha 4 DEFA4 4.9
Haptoglobin HP 4.8
High mobility group box 1 HMGB1 4.5
Lysozyme LYZ 4.4
Complement factor H CFH 4.3
C-C motif chemokine ligand 5 CCL5 4.2
Ribonuclease A family member 4 RNASE4 3.6
Interleukin 1 receptor type 1 IL1R1 3.6
Complement C1q B chain C1QB 3.5
Lipopolysaccharide binding protein LBP 3.3
Bactericidal/permeability-increasing protein BPI 3.2
Interleukin 18 binding protein IL18BP 2.9
Ribonuclease A family member 3 RNASE3 2.4
Immune response: others
Interferon stimulated exonuclease gene 20 kDa ISG20 24.2
Myxovirus resistance 1, interferon-inducible protein p78 MX1 8.7
2′-5′-oligoadenylate synthetase 2, 69/71 kDa (OAS2) OAS2 8.54
CD55 molecule, decay accelerating factor for complement CD55 6.7
B-cell CLL/lymphoma 6 (zinc finger protein 51) BCL6 4.9
Complement component 1, s subcomponent (C1S) C1S 4.9
Hect domain and RLD 5 HERC5 4.7
CD300 molecule-like family member g (CD300LG) CD300LG 4.4
V-ets erythroblastosis virus E26 oncogene homolog 1 ETS1 4.2
Bone marrow stromal antigen 2, Tetherin (CD317) BST2 3.3
Mitogen-activated protein kinase kinase kinase 8 MAP3K8 3.1
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3 DDX3× 3
Interferon induced transmembrane protein 1 IFITM1 3
Interferon induced with helicase C domain 1 IFIH1 3
Sequestosome 1 SQSTM1 3
FYN oncogene related to SRC, FGR, YES (FYN) FYN 2.8
Interferon regulatory factor 7 IRF7 2.8
TANK-binding kinase 1 TBK1 2.7
Adenosine deaminase, RNA-specific, B1 ADARB1 2.7
Interferon-induced protein with tetratricopeptide repeats 2 IFIT2 2.6
Interferon-induced protein with tetratricopeptide repeats 3 IFIT3 2.6
Radical S-adenosyl methionine domain containing 2 RSAD2 2.5
Tripartite motif-containing 56 TRIM56 2.5
Yamaguchi sarcoma viral related oncogene homolog LYN 2.4
PR domain containing 1, with ZNF domain PRDM1 2.4
Table 2. All immune-related transcripts with at least 2-fold higher expression in CBFs compared to fibroblasts 
derived from Gene ontology analysis using DAVID. Immune related molecules with over 22-fold higher levels 
compared to fibroblasts are also present in Table 1 (highly expressed).
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functional longevity of CBF immunomodulation including a possibility of protracted release of soluble immuno-
suppressive factors such as TGF-β1 and osteopontin from the bone matrix32,44.
In addition to therapeutic implications, this study proposes a new, standardised 3D in vitro model to inves-
tigate the interface between bone surface-resident cells and the immune system45 For example, their roles in 
immune cell retention and transit46,47, skeletal ageing48 or bone marrow response to infections49. Given the 
highly-controlled method of CBF tissue processing, these questions can be systematically addressed in vitro and 
in vivo, and provide future insights into the physiology of bone marrow microenvironment in humans.
Materials and Methods
Ethics statement. Written informed consent was obtained from every study participant before the sample 
was taken and research was carried out in compliance with the Helsinki Declaration. The bone marrow samples 
used to extract MSCs for this study were collected under ethical approval, 06/Q1206/127, National Research 
Ethics Committee Yorkshire and Humber–Leeds East, and peripheral blood was collected under the study num-
ber 04/Q1206/107. All experiments were performed in accordance with relevant guidelines and regulations.
Cancellous bone fragments (CBF) processing. Cancellous bone fragments (Osteocel® allograft cellular 
bone matrix, 5 cc) from 15 different research consented donors (Nuvasive, San Diego, CA, USA) were prepared, 
according to The American Association of Tissue Banks (AATB) standards, by the manufacturer using extensive 
washes in order to remove the bulk of blood-lineage cells and cryopreserved11. For determination of cellular 
composition, CBFs were digested using 0.25% collagenase (Stem Cell Technologies, Grenoble, France)11 and the 
released cells were stained with antibodies against CD271-APC (Miltenyi Biotec), CD90-FITC, CD105-PE (both 
from BioRad, UK), CD73-PerCP-CyTM5.5 and CD45-PE-Cy7 (both from BD Biosciences) as well as aqua fluo-
rescent dye and Calcein AM from the live/dead violet viability/vitality kit (Thermo Fisher Scientific-Invitrogen) 
in order to identify native bone-resident MSCs11. Following gating for single cells, these MSCs were identified 
as reported before11,14,41 and recorded as a proportion of total live cells. Other CD45-negative CBF-resident cells 
were identified as: erythroid-lineage (CD235a+) and endothelial-lineage (CD31+), whereas other hematopoietic 
CD45+ cells were identified and subdivided into lymphoid-lineage (CD3+ and CD19+) and myeloid-lineage 
(CD33+). The antibodies used were: CD3-FITC, CD19-FITC, CD271-PE-Vio®770, CD31-APC and 
CD235a-APC-Vio®770 (all from Miltenyi Biotec), CD33-Alexa Fluor®700 and CD45-BUV395 (both from BD 
Biosciences). BST2/tetherin expression on different lineage cells was measured using CD317-PerCP-CyTM5.5 
(from BioLegend, UK). The data acquisition was performed on LSRII 4 laser flow cytometer (BD Biosciences), 
and the analysis was conducted using FACS DIVA software (BD Biosciences).
CD4 T cells isolation, labelling and stimulation. To ensure consistency between experiments utilising 
different donor-derived CBFs, peripheral blood samples were taken from a single consented healthy donor. We 
have selected purified CD4+ T cells based on ISCT recommendation for testing the potency of MSC-related 
immunomodulation50. CD4 T cells were isolated using the two-step CD3+CD4+ T cell isolation kit (Miltenyi 
Biotec, Surrey, UK) via the depletion of non-CD4 cells followed by depletion of CD25+ Tregs. Purified T cells 
were labelled with the carbocyfluorescein succinimidyl ester dye analogue, CellTrace™ Violet (Thermo Fisher 
Scientific), and stimulated to proliferate using Anti-Biotin MACSiBead™ particles preloaded with biotinylated 
CD2, CD3, and CD28 antibodies (Miltenyi Biotec); these were used at bead:T cell ratio of 2:1 for best stimulation 
condition in the presence or absence of CBFs, as described below.
Co-cultures of CBFs and T cells. The CBFs (replicates of the same weight of approximately 250 mg) were 
placed in 24-well standard tissue culture plates and co-cultured with raising numbers of T cells. The ratios were 
corresponding to 0.5, 1, 2, 4, and 8 × 106 T cells/gram of CBF in a total volume of 1 mL of medium per well. The 
medium was a 1:1 mixture of Glutamax™ RPMI 1640 medium (Thermo Fisher Scientific) supplemented with 
10% FCS (Sigma-Aldrich, Dorset, UK) and StemMACS NH medium (Miltenyi Biotec), and the co-cultures were 
maintained in this medium for 5 days. For T cell proliferation suppression experiments, control culture wells 
(without CBFs) included: unstimulated T cells and stimulated T cells. In some experiments, anti-TGFß neutralis-
ing antibody or IgG1 isotype control antibody (R&D Systems) was added to cultures (ratio 1 × 106 T cell/gm CBF) 
at 5 μg/ml at the start of co-culture and kept for five days. For non-contact transwell experimental conditions, 
transparent PET membrane cell culture inserts were used, 1.0 μm pore size, 1.6 × 106 pores/cm2 (Corning) to 
allow maximum diffusion and separation between the T cells and CBFs.
For the analysis of T cell proliferation suppression, culture media was separated from CBFs, and T cells were 
isolated from culture media by pipetting and centrifugation and stained with 7AAD, CD90-FITC, CD45-APC 
and CD4-APC-Vio770. Following sequential gating for CD45+CD90− cells (non-MSCs) and then CD4+ T 
cells (Fig. 1a), the T cell proliferation was analysed using ModFit software version 3.2 (Verity Software House, 
Topsham, ME. USA) algorithm for cell generations boundaries detection and computing. T cell division index 
(DI) was calculated as the total number of T cell divisions divided by T cell number at the start of culture51. The T 
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Co-cultures of 2D culture-expanded MSCs and T cells. To assess the extent of CBF-driven immu-
nomodulation in comparison with standard 2D-cultured MSCs, bmMSCs (n = 4, passage 4–6) from healthy 
donors were used instead of CBFs in co-cultures with purified stimulated CD4 T cells as described above. 
Before co-cultures, the purity of 2D-cultured MSCs was confirmed using CD73-PE, CD90-FITC, CD105-APC, 
CD45-PE-Cy7, CD14-PE, and HLA-DR-APC-H7. MSCs were co-cultured with T cells in at ratios 1:1, 2:1, 4:1, 
and 8:1 for 5 days as described before11 then T-cell suppression index was calculated to measure inhibition of T 
cell proliferation.
Measuring PGE2 and TGF-ß1 in co-culture supernatants using ELISA. The supernatants of 
bone/T-cell co-cultures were collected at the end of five days and kept frozen (−80 °C). The levels of PGE2 and 
TGF-ß1 were measured using ELISA kits (R&D systems) according to the manufacturer’s recommendations and 
the optical readings were taken using MULTISCAN EX reader equipped with Ascent software (Thermo electron 
corporation). Control wells included media, CBF-conditioned media and stimulated T cells in the absence of 
CBFs.
Assessment of CBF immunomodulatory gene expression profile. To investigate whether CBFs 
express immunomodulatory genes before their contact with T cells, total RNA from 6 CBF samples was extracted 
using RNeasy Mini Kit (Qiagen, Germantown, MD) and used to generate a gene expression profile for each 
sample using the Illumina Bead Chip (HumanHT −12 v3). Human skin fibroblasts RNA (Cell Applications, Inc., 
CA, USA) was used as a control. Data analysis included gene identifiers, normalization and log2 transformation 
for signal values for each gene and hypothesis testing using one-way ANOVA or t-Test as appropriate. The top 50 
molecules significantly over-expressed in CBFs compared to fibroblasts were assigned into categories based on 
Gene ontology and KEGG pathway analysis using the STRING database54,55. Additionally, all transcripts signif-
icantly over-expressed in bone fragments (over 2-fold difference) were further examined for functional annota-
tion clustering using DAVID and the molecules appearing in the Immunity cluster were further subdivided into 
‘secreted’ and ‘other’ groups based on individual protein’s information provided by STRING.
To validate gene array data, the quantitative RT-PCR assays were performed for some transcripts comparing 
CFBs and fibroblasts. The RNA was extracted from the digested CFBs and cultured fibroblasts using Single Cell 
RNA purification kit (Geneflow Ltd, Lichfield, UK). The complementary DNA (cDNA) was produced using high 
capacity reverse transcription kit (Thermo Fisher Scientific). The TaqMan probes (Thermo Fisher Scientific) for 
were used for the genes: Secreted phosphoprotein 1 (SPP1) HS00959010_m1, Bone gamma-carboxyglutamate 
protein (BGLAP) HS01587814_g1, Fatty acid binding protein 4 (FABP4) HS00609791_m1, Tetherin (BST2) 
Hs00171632_m1, Interferon-stimulated gene 20 (ISG20) Hs00158122_m1, Interferon-induced GTP-binding 
protein (MX1) Hs00895608_m1, Vascular cells adhesion molecules (VCAM1) Hs01003372_m1, Nerve Growth 
Factor Receptor (NGFR) Hs00609976_m1, (S100A8) Hs00374264_g1, (S100A9) Hs00610058_m1 and (S100A12) 
Hs00942835_g1. The PCR assays were run in duplicates using 384-well plates on QuantStudio™ 7 Flex Real-Time 
PCR System (Thermo Fisher Scientific). The gene expression levels were assessed relative to the housekeeping 
gene, hypoxanthine guanine phosphoribosyl transferase (HPRT1) HS99999909_m1.
Statistical analysis. The statistical analysis and figures’ preparation was performed using GraphPad prism 6 
software. The comparative statistical tests were chosen according to the data normal distribution tested using the 
Shapiro-Wilk normality test and included Spearman rho for correlation, Mann Whitney tests, one-way ANOVA 
or t-Test were used as appropriate. Any difference between the groups was considered as statistically significant 
when the p value < 0.05.
Data Availability
The microarray gene expression array data that support the findings of this study is available from NuVasive, Inc., 
but restrictions apply to the availability of this data, which was used under license for the current study, and so is 
not publicly available. The data is however available from the corresponding author upon reasonable request and 
with permission of NuVasive, Inc.
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